Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab plus Chemotherapy in Gastric Cancer
NCT04139135Phase 3Unknown
- Sponsor
- Henlius
- Start
- Dec 2019
- Primary completion
- Oct 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of serplulimab in gastric cancer (GC) (2 arms), sponsored by Henlius. Primary endpoint: Event-Free Survival at 3 years. Status: unknown.
02
Drugs
serplulimab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT04139135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04139135.